Get the Stockscreener App
30.00
0.17%
-0.05
Lb Pharmaceuticals Inc stock is traded at $30.00, with a volume of 513.12K.
It is down -0.17% in the last 24 hours and up +8.15% over the past month.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
See More
Previous Close:
$30.05
Open:
$31
24h Volume:
513.12K
Relative Volume:
2.19
Market Cap:
$860.30M
Revenue:
-
Net Income/Loss:
$-38.95M
P/E Ratio:
-20.19
EPS:
-1.4857
Net Cash Flow:
$-50.43M
1W Performance:
+5.12%
1M Performance:
+8.15%
6M Performance:
+52.28%
1Y Performance:
+0.00%
1-Day Range:
$29.27
$31.49
1-Week Range:
$27.37
$31.49
52-Week Range:
$13.36
$33.47
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
30.00 | 861.73M | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
| Apr-10-26 | Initiated | Craig Hallum | Buy |
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
View All
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Institutional Confidence - TradingKey
LB Pharmaceuticals Inc (LBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LB Pharmaceuticals Inc (LBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LB Pharmaceuticals Inc (LBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LB Pharmaceuticals Inc (LBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LB Pharmaceuticals Inc (LBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LB Pharmaceuticals Inc (LBRX) Edges Lower Amidst Tight Trading RangeVolatility Stop - newsline.com
LBRX Q1 2026 Earnings: Narrower Loss Surpasses Estimates as Pre-Revenue Biotech Tightens SpendingFinal Results - newsline.com
LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition - Stock Titan
LB Pharmaceuticals Inc Announces Resignation of Anna Eramo as Chief Medical Officer, Effective June 15, 2026 - marketscreener.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
[144] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals Stockholders Approve Directors and Auditor - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) elects board and ratifies auditor in 2026 - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) investors back board slate and ratify BDO as 2026 auditor - Stock Titan
LBRX Options Volatility — NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc (LBRX) Shows Modest Uptick as Stock Holds Above Key SupportPut Spread Alert - newsline.com
LBRX Q1 2026 Earnings: EPS Beat Estimates as Biotech Advances PipelineEarnings Quality Score - newsline.com
LB Pharmaceuticals (LBRX) Slips 1.28% as Stock Holds Above Key Support — What's Next?Reversal Trade - newsline.com
LB Pharmaceuticals (LBRX) grants director 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) awards 10,000 options to director vesting in 2027 - Stock Titan
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals (LBRX) director receives 12,500 stock options at $27.95 strike - Stock Titan
LB Pharmaceuticals (LBRX) director receives 10,000 stock options at $27.95 strike - Stock Titan
Director at LB Pharmaceuticals (LBRX) receives grant of 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) director awarded 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) AGM 2026 Summary - Quartr
LBRX: All proposals passed, electing directors and ratifying the auditor for 2026 - TradingView
LB Pharmaceuticals Inc (LBRX) Q1 2026 Earnings: EPS Surprise on Lower-Than-Expected LossOperating Income Trends - newsline.com
LB Pharmaceuticals (LBRX) Q1 2026 Earnings: EPS Surprise Signals Improving Operational DisciplineBook Value Growth - newsline.com
LBRX News Today | Why did LB Pharmaceuticals stock go up today? - MarketBeat
Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks - Stock Titan
LBRX Options Chain — NASDAQ:LBRX - TradingView
Top LB Pharmaceuticals (LBRX) Competitors 2026 - MarketBeat
LB Pharmaceuticals to Participate in Upcoming June Investor Events - GlobeNewswire
Bipolar Depression Market Poised for Robust Growth with Upcoming Novel Therapies and Improved Diagnostics - Barchart.com
All you need to know about LB Pharmaceuticals Inc (LBRX) rating upgrade to buy - MSN
Clear Street initiates LB Pharmaceuticals stock with buy rating - Investing.com
Clear Street initiates LB Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
LB Pharmaceuticals Inc (LBRX) Edges Higher Amid Sector Strength – Key Levels in FocusPoint of Control - The Legal Advocate
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target - Investing.com UK
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential - TipRanks
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy - Yahoo Finance
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target By Investing.com - Investing.com Australia
LB Pharmaceuticals (LBRX) Holds Near Resistance as Modest Gain Signals ConsolidationHigh Volume Node - The Legal Advocate
LB Pharmaceuticals Inc (LBRX) Holds Steady Near Resistance as Market Watches for BreakoutCovered Call Trade - Newser
LB Pharmaceuticals Inc (LBRX) Breaks Higher as Volume Picks Up; Key Resistance AheadRetail Trader Picks - Newser
Why Is LB Pharmaceuticals Inc Common Stock (LBRX) Stock Down Today? - Meyka
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):